Early research suggests that repeated low-level red light therapy (RLRL) holds promise for myopia control, primarily based on studies conducted in China. But what about its efficacy in UK patients? Join Dr. Neema Ghorbani Mojarrad of the University of Bradford at recent global optometry conference as he tells us about his UK audit of the Eyerising Myopia Management Device. He discusses the device’s proposed mechanism of action, and his preliminary study results, with prosiming resutlts regarding patient compliance and slowing eye growth. For more on this newcomer to the myopia control landscape, contact an Eyerising International representative or head to the Eyerising International website at https://www.eyerisinginternational.com/.
